Fluidigm Corporation Announces Early Access Program For New Imaging Mass Cytometry Platform
8/1/2014 10:39:10 AM
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Fluidigm Corporation (NASDAQ:FLDM) has begun accepting applications to an early access program for its upcoming imaging mass cytometry platform. Prototypes of the product are expected to begin shipping to early access partners by the end of this year. The technology – laser ablation of a sample in combination with inductively coupled plasma mass spectrometry – builds upon the foundation of Fluidigm’s CyTOF® mass cytometry platform to obtain spatial resolution of protein expression in samples at the single-cell level. Today, tissue imaging is typically conducted using microscopes, where much of the information is qualitative and the technique faces severe limitations in the number of proteins that can be stained and visualized concurrently. Fluidigm’s new technology is projected to bring quantitative measurement (using metal isotope tagging that is a basis of the CyTOF technology) into this field, while offering analysis of more than 30 proteins and resolution down to about one micron.
Help employers find you! Check out all the jobs and post your resume.
comments powered by